MedTech Acquisition Corp (MTAC) to Combine with TriSalus Life Sciences in $234M Deal

MedTech Acquisition Corporation (NASDAQ:MTAC) has entered into a definitive agreement to combine with drug developer TriSalus Life Sciences at an enterprise value of $234 million. Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device. The combined company is expected to trade on the Nasdaq under the
Read More